Our data revealed that downregulation of METTL3 and hypomethylation mediate OS-induced endothelial dysfunction and atherogenesis both in vivo and in vitro, indicating that the THBS1/EGFR axis is a key regulatory target of METTL3-dependent EC activation. The gene discussed is EGFR; the disease is endothelial dysfunction.